Aclaris buys kinase-focused Confluence | August 21, 2017 Issue - Vol. 95 Issue 33 | Chemical & Engineering News
Volume 95 Issue 33 | p. 18 | Concentrates
Issue Date: August 21, 2017 | Web Date: August 20, 2017

Aclaris buys kinase-focused Confluence

Department: Business
Keywords: Biotechnology, immunology, Pfizer

Confluence Life Sciences, a St. Louis-based developer of kinase inhibitors for cancer and other diseases, has been acquired by Aclaris Therapeutics for $10 million in cash and stock. Dermatology-focused Aclaris says the deal adds a preclinical inhibitor of the MK2 pathway, implicated in arthritis and other autoimmune diseases, as well as earlier-stage molecules targeting other inflammation pathways. Confluence was founded by former Pfizer scientists after layoffs at the big pharma firm’s St. Louis site in 2009.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment